Company / Operating Income
Vistagen Therapeutics, Inc. Operating Income History
FY2011-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$47.8M
FY2023
5-year range
-$47.8M / -$10.2M
FY2019-FY2023
Trend
-166.4%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Income has fluctuated over the past 8 years, ranging from -$48M in FY2023 to -$7M in FY2011.
Based on SEC 10-K filings.
-$48M in FY2023.
Declined from -$21M to -$48M over the past 2 years.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2023, operating income decreased 166.4% year-over-year.
- Peak operating income was recorded in FY2011.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -7.17 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2023 | -$47.8M | -166.4% |
| FY2022 | -$17.9M | +13.8% |
| FY2021 | -$20.8M | -103.0% |
| FY2018 | -$10.2M | +42.6% |
| FY2017 | -$17.9M | -162.8% |
| FY2014 | -$6.8M | +24.9% |
| FY2012 | -$9.0M | -37.8% |
| FY2011 | -$6.6M | - |
As of FY2023 · SEC 10-K · Updated Jun 28, 2026